2.63 USD
↘ 0.11 (4.01%)AT CLOSE (11:59 AM EDT)
Editas Medicine, Inc. Common Stock
EDITNASDAQ • USD
2.63
↗ 0.00 (0.15%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
2.63
↗ 0.00 (0.15%)
Market: CLOSED
Editas Medicine, Inc. Common Stock (EDIT) trades at $2.64 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, EDIT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Sep 15, 2026.
Open?$2.70
High?$2.71
Low?$2.59
Prev. Close?$2.74
Volume?1.7M
Avg. Volume?2.4M
VWAP?$2.63
Rel. Volume?0.70x
Bid / Ask
Bid?$2.24 × 100
Ask?$3.06 × 100
Spread?$0.82
Midpoint?$2.65
Valuation & Ratios
Market Cap?420.8M
Shares Out?153.6M
Float?148.8M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?4.00
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Employees
87
Market Cap
420.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-02-03
Address
11 HURLEY ST.
CAMBRIDGE, MA 02141
Phone: 617-401-9000
CAMBRIDGE, MA 02141
Phone: 617-401-9000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?0
Momentum?85
Short Sent.?35
Piotroski F-Score?4/9Mixed
Altman Z-Score?-8.05Distress
Confidence?51%Low
Short InterestSqueeze Risk
Short % of Float?20.31%Squeeze Risk
Short Interest?30.2M
Days to Cover?9.0
Free Float148.8M
Avg Daily Volume3.4M
Settlement Date2026-08-31
Financial Health
Current Ratio?3.19Strong
Quick Ratio?3.19Strong
Cash Ratio?2.66Strong
Debt/Equity?0.53Moderate
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.00FAIR▾
Peers25
S&P44
P/S?8.95HIGH▾
Peers100
S&P10
P/FCF?N/A▾
EV/EBITDA?-3.6CHEAP▾
S&P97
EV/Sales?6.27HIGH▾
Peers100
S&P26
Returns & Efficiency
ROE?-70.2%WEAK▾
S&P3
ROA?-31.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-120550000
Enterprise Value?$294.7M
Fundamentals ratios updated end of day